"Isoniazid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
| Descriptor ID |
D007538
|
| MeSH Number(s) |
D02.442.436 D03.066.349.410 D03.383.725.394.582
|
| Concept/Terms |
Isoniazid- Isoniazid
- Isonicotinic Acid Hydrazide
- Hydrazide, Isonicotinic Acid
Phthivazide- Phthivazide
- Phthivazid
- Isonicotinic Acid Vanillylidenehydrazide
- Acid Vanillylidenehydrazide, Isonicotinic
- Vanillylidenehydrazide, Isonicotinic Acid
- Ftivazide
|
Below are MeSH descriptors whose meaning is more general than "Isoniazid".
Below are MeSH descriptors whose meaning is more specific than "Isoniazid".
This graph shows the total number of publications written about "Isoniazid" by people in this website by year, and whether "Isoniazid" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2017 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Isoniazid" by people in Profiles.
-
Jaecklein E, Papavinasasundaram K, Ostroff GR, Sassetti C, Soto ER. Targeted delivery of antitubercular drugs using glucan lipid particles. Microbiol Spectr. 2025 Mar 04; 13(3):e0274424.
-
Sparks IL, Derbyshire KM, Jacobs WR, Morita YS. Mycobacterium smegmatis: The Vanguard of Mycobacterial Research. J Bacteriol. 2023 01 26; 205(1):e0033722.
-
Amisi JA, Carter EJ, Masini E, Szkwarko D. Closing the loop in child TB contact management: completion of TB preventive therapy outcomes in western Kenya. BMJ Open. 2021 02 23; 11(2):e040993.
-
Umapathi A, Nagaraju NP, Madhyastha H, Jain D, Srinivas SP, Rotello VM, Daima HK. Highly efficient and selective antimicrobial isonicotinylhydrazide-coated polyoxometalate-functionalized silver nanoparticles. Colloids Surf B Biointerfaces. 2019 Dec 01; 184:110522.
-
Sakatos A, Babunovic GH, Chase MR, Dills A, Leszyk J, Rosebrock T, Bryson B, Fortune SM. Posttranslational modification of a histone-like protein regulates phenotypic resistance to isoniazid in mycobacteria. Sci Adv. 2018 05; 4(5):eaao1478.
-
Czapka M, Shukla S, Slosar-Cheah M. Urine trouble: genitourinary tuberculosis and subsequent DRESS syndrome. BMJ Case Rep. 2017 Aug 07; 2017.
-
Szkwarko D, Hirsch-Moverman Y, Du Plessis L, Du Preez K, Carr C, Mandalakas AM. Child contact management in high tuberculosis burden countries: A mixed-methods systematic review. PLoS One. 2017; 12(8):e0182185.
-
Hao N, Chen X, Jeon S, Yan M. Carbohydrate-Conjugated Hollow Oblate Mesoporous Silica Nanoparticles as Nanoantibiotics to Target Mycobacteria. Adv Healthc Mater. 2015 Dec 30; 4(18):2797-801.
-
Baek SH, Li AH, Sassetti CM. Metabolic regulation of mycobacterial growth and antibiotic sensitivity. PLoS Biol. 2011 May; 9(5):e1001065.
-
Sada-Ovalle I, Sk?ld M, Tian T, Besra GS, Behar SM. Alpha-galactosylceramide as a therapeutic agent for pulmonary Mycobacterium tuberculosis infection. Am J Respir Crit Care Med. 2010 Sep 15; 182(6):841-7.